Adalimumab Market 2020 by Size, Share, Growth, Segment, Trends and Forecast to 2024


Global “Adalimumab Market” report forecast 2020-2024 investigate the market size, manufactures, types, applications and key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Adalimumab in these regions. This report also studies the global Adalimumab market share, competition landscape, status share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

About Adalimumab:

  • Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis.

    Get a Sample Copy of the Report at:

    Adalimumab Market Manufactures:

  • AbbVie
  • Amgen
  • Sandoz
  • Boehringer Ingelheim
  • Mylan
  • Biogen

    Adalimumab Market Types:

  • Adalimumab
  • Adalimumab Biosimilar

    Adalimumab Market Applications:

  • Adults
  • Children

    Inquire or Share Your Questions If Any before the Purchasing This Report:      

    Scope of this Report:

  • This report focuses on the Adalimumab in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

    The content of the study subjects, includes a total of 15 chapters:

    • Chapter 1, to describe Adalimumab product scope, market overview, market opportunities, market driving force and market risks.
    • Chapter 2, to profile the top manufacturers of Adalimumab, with price, sales, revenue and global market share of Adalimumab in 2017 and 2018.
    • Chapter 3, the Adalimumab competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    • Chapter 4, the Adalimumab breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
    • Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
    • Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
    • Chapter 12, Adalimumab market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
    • Chapter 13, 14 and 15, to describe Adalimumab sales channel, distributors, customers, research findings and conclusion, appendix and data source.

    Purchase this Report (Price 3480 USD for A Single-User License) at:

    Table of Contents of Adalimumab Market:

    1 Market Overview

    1.1 Adalimumab Introduction

    1.2 Market Analysis by Type

    1.2.1 Type 1

    1.2.2 Type 2

    1.3 Market Analysis by Applications

    1.3.1 Application 1

    1.3.2 Application 2

    1.4 Market Analysis by Regions

    1.4.1 North America (United States, Canada and Mexico)

    1.4.2 Europe (Germany, France, UK, Russia and Italy)

    1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

    1.4.4 South America, Middle East and Africa Turkey Market States and Outlook (2014-2024)

    1.5 Market Dynamics

    1.5.1 Market Opportunities

    1.5.2 Market Risk

    1.5.3 Market Driving Force

    2 Manufacturers Profiles

    2.1 Manufacture

    2.1.1 Business Overview

    2.1.2 Adalimumab Type and Applications Product A Product B

    2.1.3 Manufacture Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Adalimumab Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

    3.1 Global Adalimumab Sales and Market Share by Manufacturer (2017-2018)

    3.2 Global Adalimumab Revenue and Market Share by Manufacturer (2017-2018)

    3.3 Market Concentration Rate

    3.3.1 Top 3 Adalimumab Manufacturer Market Share in 2018

    3.3.2 Top 6 Adalimumab Manufacturer Market Share in 2018

    3.4 Market Competition Trend

    13 Sales Channel, Distributors, Traders and Dealers

    13.1 Sales Channel

    13.1.1 Direct Marketing

    13.1.2 Indirect Marketing

    13.1.3 Marketing Channel Future Trend

    13.2 Distributors, Traders and Dealers

    14 Research Findings and Conclusion

    15 Appendix

    15.1 Methodology

    15.2 Data Source

    Contact Us:

    Name: Ajay More

    Phone: US +1424 253 0807/ UK +44 203 239 8187

    Email id- [email protected]

    Our Other Reports:

    PVC Artificial Leather Market Size 2020 Industry Demand, Share, Global Trend, Industry News, Business Growth, Top Key Players Update, Business Statistics and Research Methodology by Forecast to 2024

    Screen Protector Market Size 2020 to 2024 by Manufactures Types, Applications, Regions and Forecast to 2024

    Smart Ear Tags Market Size 2020 Global Industry Key Strategies, Historical Analysis, Segmentation, Application, Technology, Trends and Opportunities Forecasts to 2026

    Global Smart Cash Registers Market Size by Manufactures, Types, Applications and Forecast 2020 to 2024

    Silicon Monoxide Market Size 2020 Global Leading Players, Industry Updates, Future Growth, Business Prospects, Forthcoming Developments and Future Investments by Forecast to 2024

  • Source link

    Set Up Your Hyperhidrosis Patients for Treatment Success

    When children and adolescents first present to George Hightower, MD, PhD, with suspected primary hyperhidrosis, he tries to gauge their level of impairment and distress.

    “I ask my patients directly: ‘Does this get in the way of doing things you enjoy?’ ” Dr. Hightower said during the virtual Pediatric Dermatology 2020: Best Practices and Innovations Conference. If they say yes, he then asks, “‘What are those things that it gets in the way of?’ Also, so that I can develop a rapport with them, I ask, ‘Is it causing you to view yourself negatively?’ I also ask them how they anticipate treatment is going to change that.”

    Dr. Hightower, of the departments of dermatology and pediatrics, University of California, San Diego, and a pediatric dermatologist at Rady Children’s Hospital, defined focal primary hyperhidrosis as focal, visible, excessive sweating for at least 6 months without an apparent cause, plus at least two of the following characteristics: bilateral and relatively symmetric, sweating that impairs daily activities, onset before age 25, at least one episode per week, family history of idiopathic hyperhidrosis, and focal sweating that stops during sleep.

    “Based on their prominence in the popular media, armpits relative to body surface area play an oversized role in our patients’ perception of well-being,” he said. “Most of all, patients’ concerns regarding their armpits include one more of the following symptoms: smelly, sweaty, red, and itchy or painful.”

    The differential diagnosis for disorders of the axilla includes irritant/contact dermatitis, folliculitis, seborrheic dermatitis, hyperhidrosis, and hidradenitis suppurativa.

    Topical antiperspirants are the preferred initial treatment. “They’re widely available, inexpensive, and well-tolerated therapies,” Dr. Hightower said. Most commercially available antiperspirants contain low-dose aluminum or other metal that keeps the sweat gland ducts from opening.

    “Most patients referred to me have failed to improve with over-the-counter antiperspirants or aluminum chloride 20%,” he said. “We start by reviewing the appropriate use of aluminum chloride 20%. If they’re using it appropriately and fail to achieve adequate control, I open the discussion to use glycopyrronium tosylate cloth 2.4%, applied daily. This can be cost prohibitive or not covered by insurance.” Other options include glycopyrrolate 1-6 mg daily and microwave-based procedural intervention.

    In a post hoc analysis, researchers examined the efficacy and safety findings by age from two phase three randomized, controlled trials of glycopyrronium tosylate in pediatric primary axillary hyperhidrosis (Pediatr Dermatol. 2019 Jan-Feb;36[1]:89-99). It was well tolerated in the 19 patients aged 9-16 years.

    “No patients discontinued from the study in this age group [because of] symptomatology,” said Dr. Hightower, who was not involved with the study. “The concerns related to this medication are related to anticholinergic effects such as blurry vision and dry mouth, but overall, randomized clinical trial data support the benefit of this medication in helping patients improve the symptoms of hyperhidrosis.”

    In an earlier study, researchers retrospectively studied children with hyperhidrosis who were treated with a mean dosage of 2 mg glycopyrronium tosylate daily (J Am Acad Dermatol 2012 Nov;67[5]:918-23). The average age of patients was 15 years. Most (90%) experienced some improvement and 71% of those who responded saw major improvement. This occurred within hours of administration and disappeared within a day of discontinuation.

    The two most common side effects were dry mouth (26%) and dry eyes (10%). More worrisome side effects were associated with higher dosing, including blurring of vision (3%) and sensation of palpitations (3%).

    When patients return for their first follow-up appointment after starting a treatment plan, Dr. Hightower revisits their level of impairment and distress with hyperhidrosis. “I ask, ‘Remember that activity that you were doing before that this was getting in the way of? Are you doing that more? Do you feel like you can do that in a way that you weren’t able to do before, whether it’s playing an instrument or spending time with friends?’ ”

    He also sets expectations with patients and their families with comments such as, “If this treatment does not work for you after 2 months, the next option I would consider is …” and, “for most people there is no cure, but treatment is helpful.” He also emphasizes the importance of follow-up care, so they “come back to assess the next steps.”

    Dr. Hightower reported having no financial disclosures.

    This article originally appeared on

    Source link

    Cleveland Clinic Abu Dhabi Offers Integrated Palliative Care for Chronic Skin Disease

    Doctors at Cleveland Clinic Abu Dhabi, part of Mubadala’s healthcare network, are encouraging patients with skin conditions to seek medical treatment, as innovative therapies are now available in the UAE.

    Patients with recurring inflammation, abscesses and scarring in the armpits, groins or under the breasts may be suffering from Hidradenitis Suppurativa, a long-term skin condition that occurs due to the inflammation of the apocrine sweat glands.

    The condition more commonly affects females and is more pronounced in young adults, starting at puberty up to age 55. Globally, it affects 1 to 4 per cent of the population, but experts say this is likely underestimated because of underreporting and misdiagnosis.

    “Hidradenitis Suppurativa is rarely life-threatening but can be extremely painful and cause a mental health challenge for patients. It is a disfiguring disease that affects sensitive areas causing embarrassment to patients, who shy away from seeking treatment. This leads to depression, anxiety and social isolation,” says Dr. Rafal Iskanderian, an Associate Staff Physician in the Digestive Disease Institute at Cleveland Clinic Abu Dhabi.

    “The skin looks like it is burnt and is discolored because of chronic inflammation over the years. It starts with small painful lumps that recur and rupture, oozing pus after a few days. If not addressed, new lumps will continue to develop in the area nearby, making it more challenging to treat. Patients should find the right clinic when they begin to notice these changes, since a multidisciplinary approach can significantly improve their quality of life.”

    Cleveland Clinic Abu Dhabi has now established a Hidradenitis Multidisciplinary Team, which includes general and plastic surgeons, dermatology and wound care experts, and psychiatry support and infectious disease experts, that provides modern comprehensive care to patients.

    While the actual cause of the disease remains unknown, the lumps develop because of blocked hair follicles, causing an inflammation that spreads to neighboring sweat glands.

    Dr. Iskanderian says the condition is genetic in about a third of all cases. “Lifestyle factors like smoking and obesity are also strongly linked to this disease. These patients are more prone to develop autoimmune disorders like inflammatory bowel disease, especially Crohn’s disease, diabetes and thyroid disorders. A multidisciplinary approach can also help with screening these potential disorders.”

    Not addressing the issue on time, he says, can lead to serious chronic infections, sinus tracts and severe scarring. “A few skin cancer cases arising in chronic Hidradenitis ulcers have also been reported in literature.”

    In its early stages, the disease can be managed by a prolonged antibiotic treatment plan and immunosuppressive therapy, but Dr. Iskanderian says that he has been seeing more patients in the late stages of the condition who require radical surgical excision of the diseased skin and staged reconstruction.

    “When they present late, the skin is already irreversibly damaged and there is little chance to treat the inflammation with antibiotics or immunosuppressant therapy. We then must radically resect all infected skin and close the defect stage-by-stage. Ultimately, we can harvest a skin graft from the patient’s leg to reconstruct the affected area”.

    A patient, who recently went through surgical excision, says that he began seeing the lumps in his armpits and genital area nine years back.  “I was always depressed and frustrated by the condition. I would be afraid to go near my kids. I would constantly take sick days and carry an extra pair of clothes if I visited the mall because the lumps could leak fluids.”

    The 29-year-old patient says that antibiotics and immunosuppressive therapy were not working, and he opted for surgery to address the problem.

    “The medical team at Cleveland Clinic Abu Dhabi conducted the excision and grafting, which went very well. The wounds are healing fast and I’m looking forward to a full recovery soon.”

    Dr. Iskanderian adds that surgery does not cure the condition but reduces the recurrence of inflammation in the areas treated with surgery.

    “This approach has made the patients that we treated more comfortable in their bodies and has helped them regain their lost confidence. They have required less hospitalization and the immunosuppressive therapy and antibiotics are working better to manage the residual minimal disease.”

    The patient says that he can now have a normal life. “I can go out, drive a car, work-out, be with my kids, everything that I was missing out on for so long. Cleveland Clinic Abu Dhabi has a great medical team and their attention and ongoing care has changed my life.”

    For more information or to book an appointment at Cleveland Clinic Abu Dhabi, call 800 8 CCAD (2223) visit or download the Cleveland Clinic Abu Dhabi app.

    Source link

    Tumor Necrosis Factor (TNF) Inhibitor Drugs Market 2020

    According to an international research report on Tumor Necrosis Factor (TNF) Inhibitor Drugs Market 2020 provides Covid-19 Impact Analysis on market-size, shares supply-demand analysis, sales value, and volume study of different industries combined with division study, with respect to important topographical regions. This report also consists of the current evolution in the global industry and crucial elements that affects the overall growth of the Tumor Necrosis Factor (TNF) Inhibitor Drugs market. The Tumor Necrosis Factor (TNF) Inhibitor Drugs market has also been categorized depending upon various sections. The important sections are also further divided into Tumor Necrosis Factor (TNF) Inhibitor Drugs sub-sections which provided a higher understanding of the entire international market and assist to make a conclusive discernment on Tumor Necrosis Factor (TNF) Inhibitor Drugs business.

    The Years Considered To Estimate the Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size:

    History Year: 2015 – 2019 | Base Year: 2019 | Estimated Year: 2020 | Forecast Year: 2020 – 2026

    Get a Sample Copy of this Report @

    Company Coverage (Sales Revenue, Price, Gross Margin, Main Products, etc.):

    Inc., UCB S.A., AbbVie Inc., Inc., Pfizer, Johnson & Johnson Services, Merck & co., Amgen Inc., Novartis International AG and Inc.

    Read out the major objectives of the Tumor Necrosis Factor (TNF) Inhibitor Drugs market report:

    Review and analyze the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market size based on its value and volume through end-users, product types, company, major regions, breakdown information from 2015 to 2020, and predicted to 2026.

    To examine the structure of the Tumor Necrosis Factor (TNF) Inhibitor Drugs market by determining its sub-segments.

    To focus on the key companies of the Tumor Necrosis Factor (TNF) Inhibitor Drugs market to define, describe as well as examine the sales, market share, volume, value, recent development, and market competition landscape.

    To analyze competitive developments including new product launches, agreements, expansions, and acquisitions in the market.

    Highlights the value and sales volume of Tumor Necrosis Factor (TNF) Inhibitor Drugs submarkets with respect to key regions.

    To share the knowledge of the key factors influencing the market growth along with drivers, growth potential, several opportunities, risk, and market-based specific challenges.

    Product Type Coverage :

    Simponi/Simponi Aria

    Application Coverage :

     Rheumatoid Arthritis
    Psoriatic Arthritis
    Crohn’s Disease
    Ulcerative Colitis
    Ankylosing Spondylitis
    Juvenile Idiopathic Arthritis
    Hidradenitis Suppurativa

    Ask for Inquire before Purchase @

    Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Regional Segmentation:

     North America



     Central & South America

     Middle East & Africa

    Table of Contents

    1 Industry Overview

    2 Industry Environment (PEST Analysis)

    3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market by Type

    4 Major Companies List

    5 Market Competition

    6 Demand by End Market

    7 Region Operation

    8 Marketing & Price

    9 Research Conclusion

    View Report TOC, Here

    Contact Us:
    Office Addresses: 420 Lexington Avenue Suite 300
    New York City, NY 10170, United States
    USA/Canada Tel No: +1-857-2390696
    Email: [email protected]

    Source link

    InflaRx Reports Q2 2020 Financial & Operating Results Nasdaq:IFRX

    • Announced encouraging results from the Phase II portion of the Phase II/III adaptive, randomized, controlled trial in patients with COVID-19 induced pneumonia, showing a trend in lower 28-day all-cause mortality rate
    • Completed end-of-Phase II meeting with the FDA for IFX-1 in hidradenitis suppurativa
    • Received positive EMA scientific advice suggesting that IHS4 could be used as primary endpoint in InflaRx´s pivotal development in hidradenitis suppurativa
    • Cash, cash equivalents and financial assets of approximately €98.9 million as of June 30, 2020

    JENA, Germany, July 30, 2020 (GLOBE NEWSWIRE) — InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial results for the three and six months ended June 30, 2020.

    “The encouraging data from the randomized exploratory first part of our study in COVID-19 are in line with the mode of action of IFX-1 and give hope that C5a inhibition with IFX-1 may be a life-saving treatment option. The results have been submitted for publication in a peer-reviewed medical journal and to a pre-print server, and we are planning an adequately controlled and powered Phase III part of the study in critically ill COVID-19 patients,” said Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx.

    Prof. Riedemann continued, “We just received the EMA scientific advice agreeing with our arguments on the limitations of the currently used score in hidradenitis suppurativa development (HiSCR) and suggesting that IHS4 could be used as the primary endpoint in our pivotal studies. Our initial interactions with both EMA and FDA related to a Phase III development program in hidradenitis suppurativa have shown us that IFX-1 is a Phase III ready drug candidate. We are working on a strategy to address the FDA´s concerns related to the suggested change in the primary endpoint and plan additional FDA interactions on this topic. Our other clinical programs with IFX-1 are moving forward in pyoderma gangraenosum and ANCA-associated vasculitis. Depending on the COVID-19 situation, we expect readouts in these indications in 2021.”

    Recent R&D Highlights

    • IFX-1 in COVID-19 induced pneumonia: In June 2020, InflaRx announced encouraging results from the first 30 patients treated in the adaptive randomized Phase II/III trial in patients with severe COVID-19 induced pneumonia.  Positive treatment trends were seen in the 28-day all-cause mortality rate and in various other endpoints.  Twenty-eight-day all-cause mortality in the IFX-1 treatment group was 13% (2 out of 15) versus 27% (4 out of 15) in the control group. In the best supportive care group, four patients died of COVID-19-induced multi-organ failure, and three of them had pulmonary embolisms reported as a serious adverse event. In the IFX-1 treatment arm, one patient died after an acute ventilator tube complication (leakage) leading to hypoxia, and one patient who met an exclusion criterion with a history of severe chronic obstructive pulmonary disease, which was not known at time point of enrollment, died of pulmonary failure.  Additionally, fewer patients in the IFX-1 treatment arm experienced renal impairment assessed by estimated glomerular filtration rates, and more patients showed reversal of blood lymphocytopenia and a greater lowering of lactate dehydrogenase concentrations as a sign of reduction in tissue damage. A temporary significant increase of D-dimer levels in the first days following IFX-1 administration was noted, as potentially an expression of induction of blood clot lysis. No statistically significant group differences on the chosen primary endpoint of relative change (%) from baseline to day 5 in oxygenation index (defined as PaO2/FiO2 ratio) were detected. However, the exploratory first part of this study was not powered to show such differences. InflaRx is now planning an adequately powered, placebo-controlled, double blinded Phase III part using 28-day all-cause mortality as the primary endpoint, an accepted regulatory primary endpoint for critical care studies.
    • IFX-1 in Hidradenitis Suppurativa (HS): In June 2020, InflaRx completed an end-of-Phase II meeting with the FDA to discuss a Phase III program for the use of IFX-1 for the treatment of HS. The FDA agreed to key proposals to support a Biologics License Application (BLA) submission, including aspects of the Phase III trial design, IFX-1 dosing, target study population, and the nonclinical and clinical pharmacology packages. While the FDA did not agree that the International Hidradenitis Suppurativa Severity Score (“IHS4”) is fit for purpose as a primary efficacy endpoint tool to support labeling, the FDA recommended that the Company obtain HS patient input to help determine the validity of the IHS4 score. The Company is now assessing different strategies for a potential pathway to regulatory approval for IFX-1 in the United States and plans to engage with the FDA on next steps.
      Additionally, the Company requested scientific advice from the European Medicines Agency (EMA) about the European pathway for regulatory approval and received feedback in July 2020. Although the EMA noted certain considerations regarding the Company’s proposal, the EMA acknowledged that HiSCR response does not account for the clinical relevance of a reduction in draining fistulas and the effort to construct a new endpoint that better captures these changes was endorsed in principle.  According to the EMA, although HiSCR was used as an endpoint in previous studies, IHS4 could be an appropriate tool to evaluate the efficacy of a novel compound in HS. The Company is working diligently to address the additional feedback received and analyzing the strategy for its Phase III development in HS.
    • IFX-1 in Pyoderma Gangraenosum (PG): The Phase IIa open label trial continues to enroll patients in the higher dose groups. Additional clinical trial sites continue to be opened to support enrollment. Results from the higher dose groups are expected in 2021.
    • IFX-1 in ANCA-associated vasculitis (AAV): In the European Phase II IXCHANGE trial, Part 2 continues to enroll patients.  Final results are expected in 2021.
    • IFX-1 in oncology: Activities are ongoing for the Phase IIa oncology program, with expected initiation in the first half of 2021.

    Financial highlights – H1 2020

    Research and development expenses incurred for the six months ended June 30, 2020
    decreased over the corresponding period in 2019 by €5.5 million. This decline was primarily due to lower contribution of expense in the period from the Phase IIb clinical development of IFX-1 in HS since this study was completed in 2019, offset by the COVID-19 trial expenses. These two factors led to a net decline of €3.7 million in third-party expenses. Furthermore third-party manufacturing expenses also declined by €1.0 million. Additionally, equity-settled share-based compensation recognized in personnel expenses decreased by €0.9 million.

    General and administrative expenses decreased by €2.1 million to €4.9 million for the six months ended June 30, 2020, from €6.9 million for the six months ended June 30, 2019. This decrease is primarily attributable to decreasing expenses associated with equity-settled share-based compensation recognized in personnel expenses (€1.5 million). Furthermore, legal, consulting and other expenses decreased by €0.7 million to €2.1 million for the six months ended June 30, 2020, from €2.8 million for the six months ended June 30, 2019. In 2019, consulting costs were higher due to a onetime strategic project.

    Net financial result decreased by €1.0 million to €1.1 million for the six months ended June 30, 2020, from €2.0 million for the six months ended June 30, 2019. This decrease is mainly attributable to lower interest earned on marketable securities (€1.1 million), partially offset by a higher foreign exchange result (higher gains €0.9 million and €0.5 million higher losses).

    Net loss for the six months ended June 30, 2020 was €18.3 million or €(0.70) per common share, compared to €25.1 million or €(0.97) per common share for the six months ended June 30, 2019. On June 30, 2020, the Company’s total funds available were approximately €98.9 million, composed of cash and cash equivalents (€36.4 million) and financial assets (€62.5 million).

    Net cash used in operating activities decreased to €18.2 million in the six months ended June 30, 2020, from €18.7 million in the six months ended June 30, 2019, mainly due to the decrease of cash expenses, such as third-party expenses for manufacturing and clinical trials for our lead program IFX-1, compensated by lower payments on trade liabilities in the six months ended June 30, 2019.
    Additional information regarding these results and other relevant information is included in the notes to the unaudited Condensed Consolidated Financial Statements as of June 30, 2020, as well as the financial statements as of December 31, 2019 in “ITEM 18. Financial statements,” which is included in InflaRx’s Annual Report on Form 20-F as filed with the U.S. Securities and Exchange Commission (SEC).

    InflaRx N.V. and subsidiaries
    Unaudited Condensed Consolidated Statements of Operations and
    Comprehensive Loss for the three and six months ended June 30, 2020 and 2019

      For the three months ended
    June 30,
    For the six months ended
    June 30,
    (in €, except for share data) 2020
    Operating Expenses        
    Research and development expenses (7,356,326 )   (12,497,222 )   (14,655,125 )   (20,192,372 )
    General and administrative expenses (2,326,895 )   (3,647,849 )   (4,891,698 )   (6,949,015 )
    Total Operating Expenses (9,683,221 )   (16,145,071 )   (19,546,822 )   (27,141,387 )
    Other income 102,332     2,866     197,292     67,702  
    Other expenses (3,450 )   (79,183 )   (9,170 )   (83,068 )
    Operating Result (9,584,339 )   (16,221,387 )   (19,358,701 )   (27,156,753 )
    Finance income 609,444     1,338,755     2,268,436     2,497,960  
    Finance expenses (1,057,937 )   (388,097 )   (1,175,964 )   (449,807 )
    Net Financial Result (448,493 )   950,659     1,092,472     2,048,153  
    Loss for the Period (10,032,832 )   (15,270,729 )   (18,266,229 )   (25,108,600 )
    Share Information        
    Weighted average number of shares outstanding 26,172,023     25,964,379     26,138,639     25,964,379  
    Loss per share (basic/diluted) (0.38 )   (0.59 )   (0.70 )   (0.97 )
    Loss for the Period (10,032,832 )   (15,270,729 )   (18,266,229 )   (25,108,600 )
    Other comprehensive income that may be re­clas­si­fied to profit or loss in subsequent periods:        
    Exchange differences on translation of foreign currency (1,452,973 )   (1,622,079 )   260,895     695,468  
    Total Comprehensive Loss (11,485,805 )   (16,892,807 )   (18,005,334 )   (24,413,132 )

    InflaRx N.V. and subsidiary
    Unaudited Condensed Consolidated Statements of Financial Position
    as of June 30, 2020 and December 31, 2019

    in € June 30,
      December 31,
    Non-current assets    
    Property, plant and equipment 493,377   576,373  
    Right-of-use assets 716,871   836,924  
    Intangible assets 404,251   452,400  
    Other assets 419,424   452,217  
    Financial assets 272,627   272,614  
    Total non-current assets 2,306,550   2,590,528  
    Current assets    
    Other assets 2,973,228   3,500,884  
    Financial assets 62,191,912   82,353,867  
    Cash and cash equivalents 36,398,578   33,131,280  
    Total current assets 101,563,718   118,986,031  
    TOTAL ASSETS 103,870,268   121,576,558  
    Issued capital 3,152,427   3,132,631  
    Share premium 211,483,756   211,006,606  
    Other capital reserves 26,627,185   25,142,213  
    Accumulated deficit (152,628,234 ) (134,362,006 )
    Other components of equity 2,488,124   2,227,228  
    Total equity 91,123,258   107,146,673  
    Non-current liabilities    
    Lease liabilities 203,636   330,745  
    Other non-financial liabilities 37,644   39,013  
    Total non-current liabilities 241,280   369,758  
    Current liabilities    
    Trade and other payables 10,630,462   12,413,662  
    Lease liabilities 524,034   515,203  
    Employee benefits 867,121   975,629  
    Social security, other tax and non-financial liabilities 448,113   105,634  
    Provisions 36,000   50,000  
    Total current liabilities 12,505,730   14,060,128  
    Total Liabilities 12,747,010   14,429,886  
    TOTAL EQUITY AND LIABILITIES 103,870,268   121,576,558  

    InflaRx N.V. and subsidiary
    Unaudited Condensed Consolidated Statements of Changes in Shareholders’ Equity for the six months ended June 30, 2020 and 2019

     (in €, except for share data) Issued
    of equity
    Balance as of January 1, 2020 3,132,631   211,006,606   25,142,213   (134,362,006 )   2,227,228   107,146,673  
    Loss for the period       (18,266,229 )     (18,266,229 )
    Exchange differences on
    translation of foreign currency
           —     260,895   260,895  
    Total comprehensive loss       (18,266,229 )   260,895   (18,005,334 )
    Equity-settled share-based pay­ment     1,484,972         1,484,972  
    Share options exercised 19,797   477,149           496,946  
    Total Contributions 19,797   477,149   1,484,972         1,981,918  
    Balance as of June 30, 2020 3,152,427   211,483,756   26,627,185   (152,628,234 )   2,488,124   91,123,258  
    Balance as of January 1, 2019 3,115,725   211,021,835   18,310,003   (81,107,188 )   50,196   151,390,571  
    Loss for the period       (25,108,600 )    —   (25,108,600 )
    Exchange differences
    on translation of foreign currency
           —     695,468   695,468  
    Total comprehensive loss       (25,108,600 )   695,468   (24,413,132 )
    Equity-settled share-based pay­ment     3,889,767    —      —   3,889,767  
    Total Contributions     3,889,767    —      —   3,889,767  
    Balance as of June 30, 2019 3,115,725   211,021,835   22,199,770   (106,215,788 )   745,663   130,867,206  

    InflaRx N.V. and subsidiary
    Unaudited Condensed Consolidated Statements of Cash Flows
    for the six months ended June 30, 2020 and 2019

    in € For the six
    months ended
    June 30, 2020

        For the six
    months ended
    June 30, 2019

    Operating activities    
    Loss for the period (18,266,229 )   (25,108,600 )
    Adjustments for:    
    Depreciation & amortization of property, plant, equipment, right-of-use assets and intangible assets 353,976     307,130  
    Net financial result (1,092,472 )   (2,048,153 )
    Share-based payment expense 1,484,972     3,889,767  
    Net foreign exchange differences (789,528 )   (205,103 )
    Changes in:    
    Other assets 560,449     (2,063,491 )
    Employee benefits (122,411 )   (84,890 )
    Social security and other current non-financial liabilities 341,012     (184,120 )
    Trade and other payables (1,783,200 )   5,513,355  
    Interest received 1,096,651     1,269,745  
    Interest paid (5,455 )   (16,308 )
    Net cash used in operating activities (18,222,235 )   (18,730,669 )
    Investing activities    
    Purchase of intangible assets, laboratory and office equipment (35,107 )   (503,881 )
    Purchase of non-current other financial assets  —     (75,543 )
    Disposal of non-current other financial assets  —     3,088  
    Purchase of current financial assets (59,196,096 )    
    Proceeds from the maturity of financial assets 56,553,296     17,709,459  
    Net cash from investing activities 20,272,857     17,133,122  
    Financing activities    
    Proceeds from exercise of share options 496,946      
    Repayment of lease liabilities (183,970 )   (125,075 )
    Net cash from/ (used in) financing activities 312,976     (125,075 )
    Net (decrease)/increase in cash and cash equivalents 2,363,597     (1,722,622 )
    Effect of exchange rate changes on cash and cash equivalents 903,700     399,266  
    Cash and cash equivalents at beginning of period 33,131,280     55,386,240  
    Cash and cash equivalents at end of period 36,398,578     54,062,885  

    About IFX-1:

    IFX-1 is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. IFX-1 has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response in pre-clinical studies. IFX-1 is believed to be the first monoclonal anti-C5a antibody introduced into clinical development. Approximately 300 people have been treated with IFX-1 in clinical trials, and the antibody has been shown to be well tolerated. IFX-1 is currently being developed for various indications, including Hidradenitis Suppurativa, ANCA-associated vasculitis, Pyoderma Gangraenosum and COVID-19 pneumonia.

    About InflaRx N.V.:

    InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information please visit


    InflaRx N.V.
    Jordan Zwick – Global Head of Business Development & Corporate Strategy
    Email: jordan.zwick[at]
    Tel: +1 917-338-6523

    MC Services AG
    Katja Arnold, Laurie Doyle, Andreas Jungfer
    Email: inflarx[at]
    Europe: +49 89-210 2280
    US: +1-339-832-0752


    This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials; the impact of the COVID-19 pandemic on the Company; the timing  of and our ability to commence and conduct clinical trials; potential results from current or potential future collaborations; our ability to make regulatory filings, obtain positive guidance from regulators, and obtain and maintain regulatory approvals for our product candidates; our intellectual property position; our ability to develop commercial functions; expectations regarding clinical trial data; our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies; the industry in which we operate; the trends that may affect the industry or us and the risks, uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

    Source link

    Should You Buy Inflarx NV (IFRX) Stock on Tuesday?

    The market has been neutral on Inflarx NV (IFRX) stock recently. IFRX gets a Neutral score from InvestorsObserver’s Stock Sentiment Indicator.

    Sentiment Score - ,neutral
    Inflarx NV has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on IFRX!

    What is Stock Sentiment?

    When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.

    Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.

    InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.

    For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

    What’s Happening With IFRX Stock Today?

    Inflarx NV (IFRX) stock has gained 7.51% while the S&P 500 is flat 0% as of 2:43 PM on Tuesday, Jul 28. IFRX is higher by $0.37 from the previous closing price of $4.93 on volume of 948,848 shares. Over the past year the S&P 500 is up 7.23% while IFRX is higher by 83.39%. IFRX lost -$2.33 per share in the over the last 12 months.

    To screen for more stocks like Inflarx NV click here.

    More About Inflarx NV

    InflaRx NV is a clinical-stage biopharmaceutical company is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company’s proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. It is also developing IFX-1 for the treatment of AAV, a life-threatening autoimmune disease associated with powerful inflammatory flares that impair kidney function and lead to fatal organ dysfunction.

    Source link

    Hidradenitis Suppurativa Market Report- by Application Analysis, End Users, Regions and Forecast to 2022

    The research reports on Hidradenitis Suppurativa Market report gives detailed overview of factors that affect global business scope. Hidradenitis Suppurativa Market report shows the latest market insights with upcoming trends and breakdowns of products and services. This report provides statistics on the market situation, size, regions and growth factors. Hidradenitis Suppurativa Market report contains emerging players analyze data including competitive situations, sales, revenue and market share of top manufacturers.

    Get FREE PDF Sample of the report @

    Top Company Profile Analysis in this Report







    and more..

    Hidradenitis Suppurativa (HS) is a chronic, inflammatory, debilitating skin disease that is characterized by the recurrent development of painful nodules and abscesses that rupture. This leads to the formation of sinus tracts and scarring on the skin. The exact cause of HS is unknown, and it is hypothesized that genetic and environmental factors are the key causes of the disease Environmental factors such as smoking, obesity, and being overweight are considered to be trigger factors in HS development. Additionally, genetic factors are also believed to play a key role in the development of HS. DNA studies have revealed that approximately one-third of patients with HS have a family history of HS. Studies have also shown that there are inheritance patterns within families who are affected by HS.

    ReportsnReports estimates the 2018 sales for the HS market at approximately $898 million across the 7MM, encompassing the US, the five major European Union countries (5EU: France, Germany, Italy, Spain, and UK) and Japan. Over the course of the 10-year forecast period, the HS market will grow at a Compound Annual Growth Rate (CAGR) of 7.2% across the 7MM. Each of the 7MM are anticipated to grow significantly, recording CAGRs of 9.9%, 1.2% and -0.5% across the US, 5EU and Japan, respectively. At the end of 2028, the US will account for 79.1% of sales across the 7MM, while the 5EU and Japan will account for around 20.9% of sales. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of HS in the region, as well as the anticipated high annual cost of therapy (ACOT) of biologics in the US market.

    Key Questions Answered
    – How will the HS market landscape in the 7MM (US, France, Germany, Italy, Spain, UK and Japan) change from 2018-2028?
    – What are the most promising late-stage pipeline drugs in HS?
    – How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
    – What are the greatest unmet needs in HS? Will the pipeline drugs fulfil these needs of the market?
    – What are the largest opportunities in the HS landscape?

    Scope of this Report-
    – Overview of HS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
    – Topline HS market revenue from 2018-2028. ACOT and major pipeline product sales in this forecast period are included.
    – Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HS therapeutics sales in the 7MM.
    – Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
    – Analysis of the current and future market competition in the global HS therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

    Reasons to buy this Report-
    The report will enable you to –
    – Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
    Develop business strategies by understanding the trends shaping and driving the global HS therapeutics market.
    – Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HS therapeutics market in the future.
    Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
    – Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
    – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

    Get FLAT 20% Discount on this Report @

    Table of Contents
    1.1 List of Tables
    1.2 List of Figures
    2 Hidradenitis Suppurativa: Executive Summary
    2.1 New Entrants Will Drive Modest Growth Across the 7MM from 2018 to 2028
    2.2 Launch of Pipeline Therapies Will Lead to Change in the HS Landscape
    2.3 High Unmet Needs Exists in the HS Market, Especially for a Highly Efficacious Treatment
    2.4 Pipeline Agents Will Offer Incremental Improvements Over Current Therapies
    2.5 What Do Physicians Think?
    3 Introduction
    3.1 Catalyst
    3.2 Related Reports
    3.3 Upcoming Related Reports
    4 Disease Overview
    4.1 Etiology and Pathophysiology
    4.1.1 Etiology
    4.1.2 Pathophysiology
    4.2 Classification or Staging Systems
    5 Epidemiology
    5.1 Disease Background
    5.2 Risk Factors and Comorbidities
    5.3 Global and Historical Trends
    5.3.1 US
    5.3.2 5EU
    5.4 Forecast Methodology
    5.4.1 Sources
    5.4.2 Forecast Assumptions and Methods
    5.5 Epidemiological Forecast for HS (2018-2028)
    5.5.1 Diagnosed Active Prevalent Cases of HS
    5.5.2 Age-Specific Diagnosed Active Prevalent Cases of HS
    5.5.3 Sex-Specific Diagnosed Active Prevalent Cases of HS
    5.5.4 Diagnosed Active Prevalent Case of HS by Severity
    5.5.5 Diagnosed Active Prevalent Cases of HS with IBD
    5.6 Discussion
    5.6.1 Epidemiological Forecast Insight
    5.6.2 Limitations of the Analysis
    5.6.3 Strengths of the Analysis
    6 Current Treatment Options
    6.1 Overview
    6.2 Diagnosis
    6.3 Treatment
    7 Unmet Needs and Opportunity Assessment
    7.1 Overview
    7.2 Lack of Efficacious Treatment
    7.3 Early Diagnosis of HS
    7.4 Lack of Treatment Options for Fibrosis
    7.5 Lack of Holistic Management of HS
    8 R&D Strategies
    8.1 Overview
    8.1.1 Biological Therapies
    8.1.2 Oral Therapies
    8.2 Clinical Trial Design
    8.2.1 Current Clinical Trial Design
    8.2.2 Limitations and Future Outlook
    9 Pipeline Assessment
    9.1 Overview
    9.2 Innovative Early-Stage Approaches
    10 Pipeline Valuation Analysis
    10.1 Clinical Benchmark of Key Pipeline Drugs
    10.2 Commercial Benchmark of Key Pipeline Drugs
    10.3 Competitive Assessment
    10.4 Top-Line 10-Year Forecast
    10.4.1 US
    10.4.2 5EU
    10.4.3 Japan
    11 Appendix

    Source link

    Dermatologist treating over 500 patients across the region who live with HS skin disease

    As a doctor, Alavi said, she can’t forget the relief she feels when she sees how relieved her patients seem, finally knowing what condition they have. However, she feels uneasy knowing the staggering statistics surrounding how the delay is affecting people with HS. 

    According to the Canadian Skin Patient Alliance, 16 per cent of HS patients have had more than 10 emergency visits before diagnosis – much too long before seeing a dermatologist, who could have diagnosed the patient and began treatment, Alavi said. 

    “If everyone came to us within the first few months of them having a boil or abscess, we could change lives,” Alavi said. “But by the time we see them, they are already depressed, and divorced … there is a scar in their life that we can’t change, and that’s from missing that window of opportunity.” 

    Alavi talked about some of the experiences her patients living with HS have shared with her. 

    One of her young patients, a girl, said she closes her eyes and dreams of going to the beach wearing a bikini.

    Another young girl, who is athletic and likes to play basketball, said her abscess burst and embarrassed her in front of her friends. 

    Then there was her patient who was a teacher and had her wedding day coming up, and her only wish was to have that one night with no abscess and to pass the night without her dress staining.

    “Very simple things” become not so simple for people with HS, Alavi said, adding that some of her patients have said their dreams are to go to bed with no pain and for a cure for HS to be found. 

    There is currently no cure for HS. However, treatments are available to help minimize it and make life more livable for patients. 

    Treatments for mild cases of HS to severe cases differ, and range from antibiotics, anti-inflammatory medications, topical medications and surgery. 

    Since COVID-19, their clinics were closed, and Alavi and her team contacted their patients to assure them they were not without care. They adapted their services and offered virtual appointments, and learned that this method was working better for them, as they could meet with more patients. “This is something we will continue doing in the future, unless people need to come in,” Alavi said. 

    “This is a genetic disease; we cannot prevent it from coming, but we can control this. If you or someone in your family had symptoms of this disease, please seek advice, stay strong and support each other,” Alavi said. 

    Source link

    Bimekizumab shows positive phase 3b results against Cosentyx

    We were unable to process your request. Please try again later. If you continue to have this issue please contact

    Bimekizumab was superior to Cosentyx for the treatment of moderate-to-severe plaque psoriasis, according to phase 3b study results released by UCB.

    The randomized, multicenter, double-blind, active comparator-controlled, parallel-group BE RADIANT trial compared UCB’s investigational IL-17A and IL-17F inhibitor bimekizumab to Cosentyx (secukinumab, Novartis). It included 743 psoriasis patients who had a baseline Psoriasis Area and Severity Index score of 12 or greater and a body surface area affected by psoriasis of 10% or greater, as well as an Investigator’s Global Assessment score equal or above 3.

    The bimekizumab group was superior to the secukinumab group in achieving a 75% improvement in PASI by week 4, and complete skin clearance at week 48.

    “Psoriasis places a heavy burden on patients, often causing pain, discomfort and stigma. Patients may not get the complete skin clearance that they want and may not even realize that it’s possible,” Emmanuel Caeymaex, executive vice president of Immunology Solutions and head of UCB in the U.S., said in a press release. “Health care providers may also feel forced to make trade-offs between therapies that work quickly, versus those that have shown durable efficacy. The BE RADIANT results demonstrate that bimekizumab has the potential to raise the treatment bar for patients and their dermatologists. UCB is proud to lead the way in connecting science to unmet patient needs and developing bimekizumab. It is our ambition to provide a transformative experience for psoriasis patients.”

    UCB is continuing to study bimekizumab’s safety and efficacy for the treatment of psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondylarthritis and hidradenitis suppurativa, the release said.


    Source link

    Hidradenitis Suppurativa Treatment Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 – 2029 – 3w Market News Reports

    With having published myriads of reports, PMR imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts deliver reports with accurate data extracted from trusted sources. We ride the wave of digitalization – facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available 24/7 to provide tailored business solutions to the clients.

    In this new business intelligence report, PMR serves a platter of market forecast, structure, potential, and socioeconomic impacts associated with the global Hidradenitis Suppurativa Treatment market. With Porter’s Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Hidradenitis Suppurativa Treatment market.

    Request Sample Report @

    The Hidradenitis Suppurativa Treatment market report has been fragmented into important regions that showcase worthwhile growth to the vendors – Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2) and region 3 (Country 1, Country 2). Each geographic segment has been assessed based on supply-demand status, distribution, and pricing. Further, the study provides information about the local distributors with which the market players could create collaborations in a bid to sustain production footprint.

    key players of the hidradenitis suppurativa treatment market are: Pfizer Inc., GlaxoSmithKline plc. AstraZeneca, Johnson & Johnson, AbbVie Inc.,  Merck & Co., Inc., TARGET Pharma Solutions, Inc.,  and Novartis AG.

    The report on Hidradenitis suppurativa treatment market covers exhaustive analysis on:

    • Market Segments
    • Market Dynamics
    • Historical Actual Market Size, 2014 – 2018
    • Market Size & Forecast 2019 to 2029
    • Supply & Demand Value Chain
    • Market Current Trends/Issues/Challenges
    • Competition & Companies involved
    • Technology
    • Value Chain
    • Market Drivers and Restraints

    Regional analysis for Hidradenitis suppurativa treatment market includes

    • North America
    • Latin America
    • Europe
    • East Asia
    • South Asia
    • Oceania
    • Middle East & Africa

     Report on Hidradenitis suppurativa treatment market highlights:

    • Shifting industry dynamics
    • In-depth market segmentation
    • Historical, current and projected industry size
    • Recent industry trends
    • Key competition landscape
    • Strategies of key players and product offerings
    • Potential and niche segments/regions exhibiting promising growth
    • A neutral perspective towards market performance

    Request Report Methodology @ 

    What does the Hidradenitis Suppurativa Treatment market report contain?

    • Segmentation of the Hidradenitis Suppurativa Treatment market to target the growth outlook and trends affecting these segments.
    • Scrutinization of the competitive landscape into market and regional penetration, acquisitions, and agreements with SWOT analysis.
    • Consumption behavior of each segment of the Hidradenitis Suppurativa Treatment market in every region.
    • Thorough analysis of the impacts of the growth of relevant industries.
    • In-depth insights about the recent R&D projects performed by each Hidradenitis Suppurativa Treatment market player.

    Readers can get the answers of the following questions while going through the Hidradenitis Suppurativa Treatment market report:

    • Which segment will have the maximum share of the global Hidradenitis Suppurativa Treatment market by the end of 2029?
    • What opportunities are available for the Hidradenitis Suppurativa Treatment market players to expand their production footprint?
    • What are the pros and cons of the Hidradenitis Suppurativa Treatment on human health?
    • Which players are entering into partnerships and why?
    • Why the demand for the Hidradenitis Suppurativa Treatment highest in region?

    And many more …

    For any queries get in touch with Industry Expert @ 

    Source link